This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / ImmunityBio Faces Securities Fraud Lawsuits
Regulatory securities fraud lawsuit

ImmunityBio Faces Securities Fraud Lawsuits

Analysis based on 132 articles · First reported Apr 02, 2026 · Last updated May 26, 2026

Sentiment
-60
Attention
4
Articles
132
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The multiple securities class action lawsuits against ImmunityBio, stemming from alleged misleading statements about its drug Anktiva and a subsequent FDA warning, have already caused a significant drop in ImmunityBio's stock price. This event creates uncertainty for ImmunityBio's future and could lead to substantial financial liabilities for the company, impacting its market valuation and investor confidence.

biotechnology pharmaceuticals legal services
Event Summary

ImmunityBio, a biotechnology company, is facing multiple securities class action lawsuits filed by law firms including Rosen Law Firm, Hagens Berman, Kessler Topaz Meltzer & Check, Bernstein Liebhard LLP, Bronstein, Gewirtz & Grossman, LLC, and The Gross Law Firm. These lawsuits allege that ImmunityBio and its Executive Chairman, Patrick Soon-Shiong, made false and misleading statements regarding the capabilities of its lead biologic product, Anktiva, particularly claims that it 'can cure and even prevent all cancer.' The United States — Food and Drug Administration issued a warning letter to ImmunityBio, stating that these promotional materials were misleading and misrepresented Anktiva's benefits. This news led to a more than 21% drop in ImmunityBio's stock price on March 24, 2026, erasing nearly $2 billion in market capitalization. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are being encouraged to join these class actions, with a lead plaintiff deadline of May 26, 2026.

Entities Involved
stock
ImmunityBio
ImmunityBio is the defendant in multiple securities class action lawsuits due to alleged misleading statements about its drug Anktiva, which caused its stock price to fall significantly. The company faces investigations and potential financial penalties.
Importance 100.0 Sentiment -70.0
per
Patrick Soon-Shiong
Patrick Soon-Shiong, ImmunityBio's Executive Chairman and Chief Scientific and Medical Officer, is accused of materially overstating Anktiva's capabilities, leading to the FDA warning and subsequent lawsuits.
Importance 90.0 Sentiment -65.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.
Importance 85.0 Sentiment 0.0
priv
Rosen Law Firm
Rosen Law Firm is actively filing and encouraging investors to join a securities class action lawsuit against ImmunityBio, seeking compensation for investors who suffered losses.
Importance 80.0 Sentiment 20.0
priv
Hagens Berman
Hagens Berman is investigating claims that ImmunityBio violated federal securities laws and is urging investors with significant losses to join their class action lawsuit.
Importance 75.0 Sentiment 15.0
priv
Kahn Swick & Foti
Kahn Swick & Foti is a law firm that has also filed a securities class action lawsuit against ImmunityBio, representing investors who suffered losses.
Importance 70.0 Sentiment 10.0
priv
Kessler Topaz Meltzer & Check
Kessler Topaz Meltzer & Check has filed a securities fraud class action lawsuit against ImmunityBio and is encouraging investors to seek lead plaintiff status.
Importance 70.0 Sentiment 15.0
priv
Pomerantz LLP
Pomerantz LLP is a law firm that has filed a class action lawsuit against ImmunityBio on behalf of investors.
Importance 70.0 Sentiment 10.0
priv
Bernstein Liebhard LLP
Bernstein Liebhard LLP has commenced a securities fraud class action lawsuit against ImmunityBio, reminding investors of the upcoming deadline to join.
Importance 65.0 Sentiment 10.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ImmunityBio and its officers, alleging violations of federal securities laws.
Importance 60.0 Sentiment 10.0
govactor
United States — United States District Court for the Northern District of California
The United States — United States District Court for the Northern District of California is the venue where at least one of the securities class action lawsuits against ImmunityBio has been filed.
Importance 60.0 Sentiment 0.0
per
Richard Adcock
Richard Adcock is the CEO of ImmunityBio and was the recipient of the FDA's warning letter regarding the misleading promotion of Nogapendekin alfa inbakicept.
Importance 40.0 Sentiment -50.0
priv
Bloomberg News
Bloomberg News reported on the FDA's warning letter to ImmunityBio, which brought the misleading claims to wider public and investor attention.
Importance 30.0 Sentiment 0.0
per
Charles Foti
Charles Foti is a partner at Kahn Swick & Foti, LLC, and a former Attorney General of Louisiana, involved in the securities class action lawsuit.
Importance 20.0 Sentiment 10.0
per
Lewis Kahn
Lewis Kahn is the Managing Partner of Kahn Swick & Foti, LLC, and is involved in reminding investors about the class action lawsuit.
Importance 20.0 Sentiment 10.0
+ 10 more entities View on Dashboard
Relationships
ImmunityBio related ↔ Patrick Soon-Shiong
ImmunityBio related ↔ United States — Food and Drug Administration
ImmunityBio related ↔ Rosen Law Firm
ImmunityBio related ↔ Hagens Berman
ImmunityBio related ↔ Kahn Swick & Foti
Patrick Soon-Shiong related ↔ United States — Food and Drug Administration
Patrick Soon-Shiong related ↔ Rosen Law Firm
Patrick Soon-Shiong related ↔ Hagens Berman
Patrick Soon-Shiong related ↔ Kahn Swick & Foti
United States — Food and Drug Administration related ↔ Rosen Law Firm
United States — Food and Drug Administration related ↔ Hagens Berman
United States — Food and Drug Administration related ↔ Kahn Swick & Foti
United States — Food and Drug Administration related ↔ Pomerantz LLP
United States — Food and Drug Administration related ↔ Bronstein, Gewirtz & Grossman, LLC
Rosen Law Firm related ↔ Hagens Berman
+ 20 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.